高级检索
当前位置: 首页 > 详情页

LncRNA KCNQ1OT1 promoted hepatitis C virus-induced pyroptosis of beta-cell through mediating the miR-223-3p/NLRP3 axis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Endocrinol & Metab, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming, Yunnan, Peoples R China
出处:
ISSN:

关键词: beta-cell hepatitis C virus (HCV) KCNQ1 overlapping transcript 1 (KCNQ1OT1) miR-223-3p pyroptosis

摘要:
Background: Type 2 diabetes is a well described extra-hepatic manifestation of hepatitis C virus (HCV) infection. This study aimed to explore the potential mechanism of KCNQ1 overlapping transcript 1 (KCNQ1OT1) in type 2 diabetes mellitus (T2DM) caused by HCV infection. Methods: Min6 cells were infected with HCV to establish a vitro model, and the HCV copy number was detected by real-time quantitative PCR (RT-qPCR). The mRNA and protein expressions of IL-10, IL 18, NLRP3, caspase-1, and GSDMD were analyzed by RT-qPCR and Western blot. Flow cytometry and TUNEL assay were used to evaluate the pyroptosis of cells and enzyme-linked immunosorbent assay (ELISA) detected the secretion of insulin. A dual luciferase reporter gene assay then verified the targeting relationship of KCNQ1OT1, miRNA-223-3p, and NLRP3. Results: KCNQ1OT1 was highly expressed in HCV-infected T2DM patients and HCV-infected 0-cells. Silencing KCNQ1OT1 inhibited 0-cell pyroptosis by regulating miR-223-3p/NLRP3, and inhibition of miR-223-3p or overexpression of NLRP3 reversed the pyroptosis by silencing KCNQ1OT1. Conclusions: Our findings indicate KCNQ1OT1 promotes HCV-infected 0-cell pyroptosis through the miRNA-223-3p/NLRP3 axis, effecting the production of insulin and accelerating the occurrence and development of T2DM.Regulating KCNQ1OT1 and its target genes will help to better understand the pathogenesis of T2DM induced by HCV infection and provide new theoretical foundations and therapeutic targets.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 肿瘤学
最新[2023]版:
JCR分区:
出版当年[2020]版:
Q3 ONCOLOGY Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Endocrinol & Metab, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China
通讯作者:
通讯机构: [1]Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Endocrinol & Metab, 157 Jinbi Rd, Kunming 650032, Yunnan, Peoples R China [*1]Department of Endocrinology and Metabolism, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Kunming 650032, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82494 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号